Investigational drug · Phase 3
REGN5713
Also called: Bremzalerbart
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Allergic Conjunctivitis.
Phase 3Last checked: Nov 19, 2026Latest source record: Apr 21, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
4
Any phase or sponsor naming "REGN5713"
First trial start
2024
Nov 19, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "REGN5713", any sponsor or status.
Conditions studied
As listed on its trial records.
- Allergic Conjunctivitis
Approved drugs for the same conditions: Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "REGN5713" as an intervention, largest first.
- Study to Assess the Efficacy of Anti-Bet v 1 Monoclonal Antibodies in Adults to Reduce Symptoms of Seasonal Allergic RhinitisPivotal-lookingCompleted
Regeneron PharmaceuticalsRegeneron (REGN)
NCT04709575 · 353 participants · Start Jan 14, 2021 · Primary completion Aug 24, 2021
Drug: REGN5713; REGN5714 and 2 more · For: Allergic Rhinitis; Conjunctivitis
Sites: Bangor, Maine; Baltimore, Maryland; Plymouth, Minnesota · 37 sites in all
- Efficacy of the Anti-Bet v 1 Monoclonal Antibodies (Given Subcutaneously) to Reduce Allergic Rhinitis and Conjunctivitis Symptoms and Skin Test Reactivity Upon Exposure to Birch Allergen in Adult ParticipantsPivotal-lookingCompleted
Regeneron PharmaceuticalsRegeneron (REGN)
NCT05430919 · 217 participants · Start Aug 15, 2022 · Primary completion Jul 31, 2023
Drug: REGN5713; REGN5714 and 1 more · For: Allergic Rhinitis; Conjunctivitis
Sites: Kingston, Canada; Mississauga, Canada; Québec, Canada
- A Study to Demonstrate the Effect of REGN5713-5715 on Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Birch Pollen AllergyPivotal-lookingCompleted
Regeneron PharmaceuticalsRegeneron (REGN)
NCT06602739 · 54 participants · Start Nov 19, 2024 · Primary completion Apr 23, 2025
Drug: REGN5713; REGN5715 and 1 more · For: Allergic Conjunctivitis
Sites: Andover, Massachusetts; Kingston, Canada; Québec, Canada
- Study of Bet v1 Antibodies Effect on Eye Allergy Symptoms in Adolescents and Adults With Birch Pollen AllergyPivotal-lookingTerminated
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07309432 · 24 participants · Start Jan 10, 2026 · Primary completion May 2, 2026
Drug: REGN5713; REGN5715 and 1 more · For: Allergic Conjunctivitis
Sites: Andover, Massachusetts; Lincoln, Nebraska
Newest research
PubMed records naming it or its code names, newest first.
- Novel antibody cocktail targeting Bet v 1 rapidly and sustainably treats birch allergy symptoms in a phase 1 study.
Gevaert P, De Craemer J, De Ruyck N, et al. · J Allergy Clin Immunol 2022
- Targeting immunodominant Bet v 1 epitopes with monoclonal antibodies prevents the birch allergic response.
Atanasio A, Franklin MC, Kamat V, et al. · J Allergy Clin Immunol 2022
Also in development for Allergic Conjunctivitis
- REGN1908FreneslerbartPhase 32 trials
Regeneron · Allergic Conjunctivitis
- REGN1909MevonlerbartPhase 32 trials
Regeneron · Allergic Conjunctivitis
- REGN5715AtisnolerbartPhase 31 trial
Regeneron · Allergic Conjunctivitis
- TL-925Phase 23 trials
Telios Pharma, Inc. · Allergic Conjunctivitis, Allergic Conjunctivitis of Both Eyes
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Regeneron.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.